Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InfuSystems HoldingsINFU -0.33%84 Earnings Yield (Joel Greenblatt) % is 6.21% as of Jun. 2026, which is 405% above its 10-year median of 1.23. GuruFocus rates INFU with a GF Score™ of 84/100 and a GF Value™ of $9.26 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 849 Medical Devices & Instruments companies, InfuSystems Holdings ranks better than 72.2% on this metric.
InfuSystems Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $214.5 Mil.
InfuSystems Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $13.3 Mil. InfuSystems Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 6.21%.
The historical rank and industry rank for InfuSystems Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
INFU'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5.19 Med: 1.23 Max: 7.09
Current: 5.02
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of InfuSystems Holdings was 7.09%. The lowest was -5.19%. And the median was 1.23%.
INFU's Earnings Yield (Joel Greenblatt) % is ranked better than 72.2% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 0.93
vs INFU: 5.02
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. InfuSystems Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 12.86%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
InfuSystems Holdings Earnings Yield (Joel Greenblatt) % Related Terms
InfuSystems Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for InfuSystems Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, InfuSystems Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InfuSystems Holdings Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where InfuSystems Holdings's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
InfuSystems Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
InfuSystems Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.3 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 6.21% mean?
InfuSystems Holdings (INFU) has a Earnings Yield (Joel Greenblatt) % of 6.21% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on InfuSystems Holdings and its competitors. This is 405% above median its historical median of 1.23. According to the industry distribution chart, InfuSystems Holdings ranks #236 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 27.8%.
Is InfuSystems Holdings' Earnings Yield (Joel Greenblatt) % too high?
InfuSystems Holdings' current Earnings Yield (Joel Greenblatt) % of 6.21% is 405% above median its 10-year median of 1.23. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.93. InfuSystems Holdings' value of 6.21% is 567.7% above this industry median. Based on the distribution chart, InfuSystems Holdings ranks #236 out of 849 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InfuSystems Holdings has a GF Score™ of 84/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InfuSystems Holdings' Earnings Yield (Joel Greenblatt) % compare to LUCD and QTRX?
According to the Medical Devices & Instruments industry distribution chart, InfuSystems Holdings ranks #236 out of 849 companies for Earnings Yield (Joel Greenblatt) %. This puts InfuSystems Holdings in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.93. InfuSystems Holdings' value of 6.21% is 567.7% above this benchmark. While the company's 10-year median is 1.23 vs. the industry median of 0.93, InfuSystems Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.93, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InfuSystems Holdings's current Earnings Yield (Joel Greenblatt) % of 6.21% is 567.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on InfuSystems Holdings and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InfuSystems Holdings's current Earnings Yield (Joel Greenblatt) % is 6.21%, which is 405% above median its own 10-year median of 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InfuSystems Holdings stock overvalued right now?
Based on GuruFocus' analysis, InfuSystems Holdings (INFU) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.26, compared to a current price of $12.19 — trading 31.6% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 6.21%, which is 405% above median its 10-year median of 1.23 and 567.7% above the Medical Devices & Instruments industry median of 0.93. InfuSystems Holdings' overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For InfuSystems Holdings (INFU), the current Earnings Yield (Joel Greenblatt) % is 6.21% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InfuSystems Holdings (INFU) Overvalued in 2026?
Based on GuruFocus' analysis, InfuSystems Holdings stock appears to be overvalued.
The current stock price of $12.19 is trading 31.6% above its estimated GF Value™ of $9.26.
GuruFocus considers InfuSystems Holdings to be Significantly Overvalued.
Key valuation signals for INFU:
Earnings Yield (Joel Greenblatt) %: 6.21% (405% above median its 10-year median of 1.23)
GF Value™: $9.26 vs. price of $12.19 (31.6% above fair value)
Industry Position: 567.7% above the Medical Devices & Instruments median (#236 of 849)
No single metric tells the full story. See the INFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
84GF Score
Get the complete analysis for INFU
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INFU has been successfully added to your 
